TScan's Losses Widen Amid Increased R&D, Revenue Jumps

Ticker: TCRX · Form: 10-Q · Filed: 2025-08-12T00:00:00.000Z

Sentiment: mixed

Topics: Biotechnology, Oncology, TCR-T Therapy, Clinical Development, Cash Burn, Biopharma, Early Stage

TL;DR

**TCRX is burning cash fast, but a revenue jump from collaborations hints at future potential, making it a speculative buy for those with high risk tolerance.**

AI Summary

TScan Therapeutics, Inc. reported a net loss of $36.95 million for the three months ended June 30, 2025, an increase from a net loss of $31.66 million in the same period of 2024. For the six months ended June 30, 2025, the net loss was $71.08 million, up from $61.80 million in the prior year. Collaboration and license revenue significantly increased to $3.08 million for the three months ended June 30, 2025, compared to $0.54 million in 2024, and to $5.25 million for the six months ended June 30, 2025, from $1.10 million in 2024. Research and development expenses rose to $32.63 million for the quarter and $62.42 million for the six months, reflecting increased investment in their TCR-T therapy product candidates. The company's cash and cash equivalents decreased from $178.69 million at December 31, 2024, to $169.39 million at June 30, 2025, while marketable securities dropped from $111.42 million to $48.65 million over the same period. TScan anticipates incurring significant losses for several more years as it continues to develop its novel cancer treatments, highlighting a substantial need for additional funding.

Why It Matters

TScan's widening net losses and significant cash burn are critical for investors, signaling continued reliance on external financing to fund its ambitious TCR-T therapy pipeline. The substantial increase in collaboration and license revenue, however, suggests potential validation of its proprietary platform and could attract future partnerships, offering a glimmer of hope in a highly competitive oncology market. For employees, continued R&D investment means job security and growth opportunities, but the long path to profitability introduces inherent risks. Customers, specifically future patients, stand to benefit from the advancement of novel cancer treatments, but the early stage of development means these therapies are years away from market availability. The broader market will watch TScan's progress as a bellwether for the viability of novel T-cell receptor therapies in solid tumors.

Risk Assessment

Risk Level: high — TScan Therapeutics has incurred significant losses since inception, with a net loss of $71.08 million for the six months ended June 30, 2025, and expects to incur losses for several more years. The company's cash and cash equivalents decreased by $9.3 million and marketable securities by $62.77 million from December 31, 2024, to June 30, 2025, indicating a substantial cash burn. This, coupled with the early stage of its product candidates and limited direct experience in conducting clinical trials as a company, points to a high-risk profile.

Analyst Insight

Investors should closely monitor TScan's cash burn rate and progress in clinical trials, particularly any announcements regarding additional financing or further collaboration agreements. Given the high-risk profile and significant capital requirements, a 'wait and see' approach is prudent for most, while aggressive investors might consider a small, speculative position if they believe in the long-term potential of TCR-T therapies and TScan's platform.

Financial Highlights

debt To Equity
N/A
revenue
$3.08M
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$36.95M
eps
N/A
gross Margin
N/A
cash Position
$169.39M
revenue Growth
+470.37%

Revenue Breakdown

SegmentRevenueGrowth
Collaboration and License Revenue$3.08M+470.37%
Collaboration and License Revenue$5.25M+377.27%

Key Numbers

Key Players & Entities

FAQ

What were TScan Therapeutics' net losses for the second quarter and first half of 2025?

TScan Therapeutics reported a net loss of $36.95 million for the three months ended June 30, 2025, and a net loss of $71.08 million for the six months ended June 30, 2025.

How did TScan Therapeutics' collaboration and license revenue change in Q2 2025?

Collaboration and license revenue for TScan Therapeutics increased significantly to $3.08 million for the three months ended June 30, 2025, up from $0.54 million in the same period of 2024.

What was the trend in TScan Therapeutics' research and development expenses?

Research and development expenses for TScan Therapeutics increased to $32.63 million for the three months ended June 30, 2025, from $26.88 million in the prior year, and to $62.42 million for the six months ended June 30, 2025, from $51.73 million.

What is TScan Therapeutics' current cash position and how has it changed?

As of June 30, 2025, TScan Therapeutics had $169.39 million in cash and cash equivalents, a decrease from $178.69 million at December 31, 2024. Marketable securities also decreased from $111.42 million to $48.65 million.

What are the primary risks for TScan Therapeutics investors?

Primary risks for TScan Therapeutics investors include significant ongoing losses, the need for substantial additional funding, the early stage of product development, and the inherent challenges and uncertainties of novel cancer treatments and clinical trials.

Does TScan Therapeutics expect to achieve profitability soon?

No, TScan Therapeutics explicitly states that it expects to incur significant losses over the next several years and may not be able to achieve or sustain revenues or profitability in the future.

What is TScan Therapeutics' core business focus?

TScan Therapeutics' core business focus is the discovery and development of T cell receptor (TCR)-engineered T cell (TCR-T) therapy product candidates for cancer treatment, based on its proprietary platform.

How many shares of voting common stock did TScan Therapeutics have outstanding as of August 8, 2025?

As of August 8, 2025, TScan Therapeutics had 52,471,405 shares of voting common stock outstanding, with a par value of $0.0001 per share.

What impact could global economic uncertainty have on TScan Therapeutics?

Global economic uncertainty and financial market volatility, caused by factors like political instability or conflicts, could make it more difficult for TScan Therapeutics to access financing and could adversely affect its business and operations.

What is the significance of the increase in TScan Therapeutics' collaboration and license revenue?

The increase in collaboration and license revenue to $3.08 million for Q2 2025 and $5.25 million for H1 2025 suggests growing external interest and potential validation of TScan Therapeutics' proprietary platform and product candidates, which could be crucial for future funding and development.

Risk Factors

Industry Context

The biotechnology sector, particularly in oncology, is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies like TScan are focused on developing novel therapies, such as cell-based immunotherapies, to address unmet medical needs. The competitive landscape is intense, with both large pharmaceutical companies and numerous emerging biotechs vying for breakthroughs.

Regulatory Implications

As a clinical-stage company, TScan is subject to stringent regulatory oversight from bodies like the FDA. The development and approval of its TCR-T therapies require successful completion of rigorous clinical trials and adherence to strict manufacturing and safety standards. Any delays or setbacks in the regulatory process can significantly impact the company's timeline and financial viability.

What Investors Should Do

  1. Monitor R&D expenditure trends: Investors should closely track R&D spending to ensure it aligns with pipeline progress and milestones. The current increase to $62.42M for H1 2025 is substantial.
  2. Assess cash runway and future funding needs: With declining cash and marketable securities and continued net losses, investors should evaluate TScan's ability to secure future funding to sustain operations beyond the current cash runway.
  3. Evaluate collaboration revenue growth: The significant increase in collaboration and license revenue to $5.25M for H1 2025 is a positive indicator of external validation and potential future income streams.
  4. Consider dilution risk: The increase in outstanding shares, though modest, warrants attention as the company may need to raise capital through equity offerings in the future.

Key Dates

Glossary

TCR-T therapy
A type of cell-based immunotherapy that engineers a patient's T-cells to express T-cell receptors (TCRs) that recognize specific antigens on cancer cells, thereby targeting and destroying the cancer. (This is the core technology platform for TScan Therapeutics, and increased R&D spending is directed towards developing product candidates based on this therapy.)
Collaboration and License Revenue
Revenue generated from agreements with other companies, typically involving licensing of intellectual property or joint development of therapeutic candidates. (This revenue stream has shown significant growth, indicating successful partnerships and potential external validation of TScan's technology.)
Net Loss
The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (TScan continues to report substantial net losses, which is typical for early-stage biotech companies investing heavily in R&D, but highlights the need for ongoing funding.)
Cash Burn Rate
The rate at which a company spends its cash reserves to cover its operating expenses, especially when it is not generating positive cash flow. (The decrease in cash and cash equivalents and marketable securities reflects TScan's ongoing cash burn as it invests in its pipeline.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, TScan Therapeutics has seen a widening net loss, with Q2 2025 losses at $36.95M versus $31.66M in Q2 2024, and H1 2025 losses at $71.08M versus $61.80M in H1 2024. This is accompanied by a significant increase in R&D expenses, reflecting continued investment in its pipeline. However, collaboration and license revenue has shown substantial growth, rising to $3.08M in Q2 2025 and $5.25M in H1 2025, indicating progress in partnerships. The company's liquidity position has weakened, with a notable decrease in marketable securities from $111.42M at year-end 2024 to $48.65M by mid-2025.

Filing Stats: 4,340 words · 17 min read · ~14 pages · Grade level 19.3 · Accepted 2025-08-12 07:30:47

Key Financial Figures

Filing Documents

Financial Statements (Unaudited)

Financial Statements (Unaudited) 6 Condensed Consolidated Balance Sheets 6 Condensed Consolidated Statements of Operations 7 Condensed Consolidated Statements of Stockholders' Equity 8 Condensed Consolidated Statements of Cash Flows 9 Notes to Unaudited Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 25 Item 4.

Controls and Procedures

Controls and Procedures 25 PART II. OTHER INFORMATION 27 Item 1.

Legal Proceedings

Legal Proceedings 27 Item 1A.

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 87 Item 3. Defaults Upon Senior Securities 87 Item 4. Mine Safety Disclosures 87 Item 5. Other Information 87 Item 6. Exhibits 87

Signatures

Signatures 88 5

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements. TScan Therapeutics, Inc. Condensed Consolidat ed Balance Sheets (in thousands, except share and per share data) (Unaudited) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 169,394 $ 178,689 Marketable securities 48,651 111,421 Prepaid expenses and other current assets 3,085 2,612 Total current assets 221,130 292,722 Property and equipment, net 9,521 7,242 Right-of-use assets 61,097 64,357 Restricted cash 5,031 5,031 Long-term deposit and other assets 1,782 1,766 Total assets $ 298,561 $ 371,118 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 4,539 $ 4,278 Accrued expenses and other current liabilities 12,797 15,410 Operating lease liability, current portion 6,288 4,570 Deferred revenue, current portion 7,698 11,698 Total current liabilities 31,322 35,956 Deferred revenue, net of current portion - 1,246 Operating lease liability, net of current portion 58,116 60,739 Long-term debt and accrued interest 32,296 32,072 Other long term liabilities 113 135 Total liabilities 121,847 130,148 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2025 and December 31, 2024 - - Voting common stock, $ 0.0001 par value; 300,000,000 shares authorized; 52,471,405 and 52,314,039 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 5 5 Non-voting common stock, $ 0.0001 par value; 10,000,000 shares authorized; 4,276,588 shares issued and outstanding at June 30, 2025 and December 31, 2024 1 1 Additional paid-in capital 622,887 616,009 Accumulated other comprehensive loss ( 4 ) 51 Accumulated deficit ( 446,175 ) ( 375,096 ) Total stockholders' equity 176,

View on Read The Filing